Abstract: Methods of treating and/or diagnosing irritable bowel syndrome (IBS) are provided, wherein treatment or diagnosis is undertaken on the basis of the patient's recordation of events associated with IBS in an event log and/or symptom diary.

Abstract: Pharmaceutical compositions for treatment of irritable bowel syndrome including non-constipated irritable bowel syndrome such as diarrhea-predominant irritable bowel syndrome and alternating constipation/diarrhea irritable bowel syndrome in male and female patients, which may comprise administering a patient with from 0.001 to 0.05 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt.

Abstract: A therapeutic method and pharmaceutical compositions for treatment of irritable bowel syndrome including non-constipated irritable bowel syndrome such as diarrhea-predominant irritable bowel syndrome and alternating constipation/diarrhea irritable bowel syndrome in male and female patients, which may comprise administering a patient with from 0.001 to 0.05 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt.

Abstract: A therapeutic method and pharmaceutical compositions for treatment of irritable bowel syndrome including non-constipated irritable bowel syndrome such as diarrhea-predominant irritable bowel syndrome and alternating constipation/diarrhea irritable bowel syndrome in male and female patients, which may comprise administering a patient with from 0.001 to 0.05 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt.

Abstract: A therapeutic method and pharmaceutical compositions for treatment of irritable bowel syndrome including non-constipated irritable bowel syndrome such as diarrhea-predominant irritable bowel syndrome and alternating constipation/diarrhea irritable bowel syndrome in male and female patients, which may comprise administering a patient with from 0.001 to 0.05 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt.

Abstract: A benzodiazepine derivative of formula (I), or a pharmaceutically acceptable salt thereof, wherein (a) R.sup.1 is --CH.sub.2 CHOH(CH.sub.2).sub.a R.sup.4 or a ketone group --CH.sub.2 CO(CH.sub.2).sub.a R.sup.5 in which a is 0 or 1 and R.sup.4 and R.sup.5 are selected from alkyl and cycloalkyl groups and saturated heterocyclic groups optionally substituted at a hetero-atom; (b) R.sup.2 and R.sup.3 are independently selected from aromatic carbocyclic and heterocylic residues; and (c) W and X are selected independently from halogen and hydrogen atoms and alkyl and alkoxy groups. These compounds are gastrin and/or CCK-B receptor antagonists.

Abstract: A benzodiazepine derivative of formula I, or a pharmaceutically acceptable salt thereof: ##STR1## wherein: (a) R.sup.4 is an alkyl, cycloalkyl or aryl group.(b) R.sup.10 is chosen from halo, OH, CH.sub.3, OCH.sub.3, NR.sup.11 R.sup.12, NO.sub.2, NHCHO, CO.sub.2 H and CN, and R.sup.11 and R.sup.12 are independently selected from H and alkyl (C.sub.1 -C.sub.5) or together NR.sup.11 R.sup.12 form a cyclic structure II, ##STR2## wherein a is 1-6; and (c) R.sup.2 is an aromatic 5- or 6-membered, substituted or unsubstituted heterocycle containing at least two heteroatoms of which at least one is nitrogen.These compounds are gastrin and/or CCK-B receptor antagonists.

Abstract: This invention relates to benzodiazepine derivatives which are useful as drugs exhibiting antagonism at the gastrin and/or CCK-B receptor, and to their production.

Abstract: This invention relates to novel benzodiazepine derivatives represented by the following general formula (I) or pharmaceutically acceptable salts thereof, ##STR1## (wherein R.sup.1 is an aryl group, or an aromatic heterocyclic radical of 5-membered monocyclic, 6-membered monocyclic or 5- and 6-membered bicyclic structure, which may optionally be substituted; and R.sup.2 is an aryl group which may optionally be substituted), to medicinal compositions comprising the same, and to a process for producing the same. The compounds of formula (I) shown above exhibit antagonism for the CCK-B receptor and the action of depressing the gastric acid secretion caused by the stimulus of pentagastrin, and are therefore useful as a drug for the relief of diseases related to the CCK-B receptor and the gastrin receptor.